CLINICAL TRIALS PROFILE FOR PIMOZIDE

All Clinical Trials for PIMOZIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004652 ↗	Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome	Completed	University of Rochester	Phase 2	1993-02-01	OBJECTIVES: I. Determine whether the time period between randomization and endpoint is longer in the short term pimozide therapy or longer term therapy in patients with Tourette syndrome. II. Determine whether tic severity, medication side effects, academic performance and psychosocial functioning are better in the short term pimozide therapy or longer term pimozide therapy.
NCT00004652 ↗	Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome	Completed	National Center for Research Resources (NCRR)	Phase 2	1993-02-01	OBJECTIVES: I. Determine whether the time period between randomization and endpoint is longer in the short term pimozide therapy or longer term therapy in patients with Tourette syndrome. II. Determine whether tic severity, medication side effects, academic performance and psychosocial functioning are better in the short term pimozide therapy or longer term pimozide therapy.
NCT00158223 ↗	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia	Completed	National Institute of Mental Health (NIMH)	Phase 4	2004-10-01	This study will assess the effectiveness of pimozide in enhancing the effects of clozapine in the treatment of schizophrenia.
NCT00158223 ↗	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia	Completed	Icahn School of Medicine at Mount Sinai	Phase 4	2004-10-01	This study will assess the effectiveness of pimozide in enhancing the effects of clozapine in the treatment of schizophrenia.
NCT00289861 ↗	Risperidone Augmentation in Patients With Schizophrenia	Completed	Stanley Medical Research Institute	Phase 4	2003-02-01	We propose a double-blind, placebo-controlled trial to study the effectiveness and tolerability of adding risperidone to stable yet only partially remitted patients with schizophrenia maintained on clozapine.
NCT00289861 ↗	Risperidone Augmentation in Patients With Schizophrenia	Completed	Massachusetts General Hospital	Phase 4	2003-02-01	We propose a double-blind, placebo-controlled trial to study the effectiveness and tolerability of adding risperidone to stable yet only partially remitted patients with schizophrenia maintained on clozapine.

Clinical Trial Conditions for PIMOZIDE

Condition Name

Condition Name for PIMOZIDE
Intervention	Trials
Schizophrenia	7
Psychotic Disorders	2
Stress Disorders, Post-Traumatic	2
Psychosis Nos/Other	1

Condition MeSH

Condition MeSH for PIMOZIDE
Intervention	Trials
Schizophrenia	7
Psychotic Disorders	4
Mental Disorders	3
Disease	3

Clinical Trial Locations for PIMOZIDE

Trials by Country

Trials by Country for PIMOZIDE
Location	Trials
United States	35
Spain	9
Canada	7
United Kingdom	2
Germany	2

Trials by US State

Trials by US State for PIMOZIDE
Location	Trials
New York	5
California	3
North Carolina	2
New Mexico	2
Connecticut	2

Clinical Trial Progress for PIMOZIDE

Clinical Trial Phase

Clinical Trial Phase for PIMOZIDE
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	2
Phase 2	7

Clinical Trial Status

Clinical Trial Status for PIMOZIDE
Clinical Trial Phase	Trials
Completed	12
Not yet recruiting	3
Withdrawn	2

Clinical Trial Sponsors for PIMOZIDE

Sponsor Name

Sponsor Name for PIMOZIDE
Sponsor	Trials
VA Office of Research and Development	2
University of Calgary	2
Stanley Medical Research Institute	2

Sponsor Type

Sponsor Type for PIMOZIDE
Sponsor	Trials
Other	30
U.S. Fed	6
Industry	2